Vered Stearns, MD, of Johns Hopkins University, and Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre, discuss two key topics in adjuvant treatment: endocrine therapy for premenopausal women with ER+ breast cancer and finding the optimal duration of treatment.
Elizabeth A. Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the growing role of immunotherapy in treating breast disease, the evidence of biomarkers that may be associated with response to therapy, and the opportunities to perform robust correlative studies.
Eun-Sil Shelley Hwang, MD, of Duke University Medical Center, discusses study findings on primary endocrine therapy for estrogen receptor–positive ductal carcinoma in situ (Abstract GS5-05).
Louis Fehrenbacher, MD, of Kaiser Permanente, discusses study findings comparing adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by weekly paclitaxel—or docetaxel and cyclophosphamide—with or without a year of trastuzumab in women with node-positive or high-risk node-negative disease (Abstract GS1-02).
Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Trust, discusses the challenges of treating metastatic breast cancer and how liquid biopsies can serve as a guide to genetic phenotypes.
Sibylle Loibl, MD, PhD, of the German Breast Group, discusses a study evaluating palbociclib plus endocrine treatment vs a chemotherapy-based treatment strategy in patients with hormone receptor–positive, HER2-negative metastatic breast cancer (Abstract OT3-05-04).
